The document mentions that by the end of 2025, a new drug for the treatment of delta hepatitis, bulvertid, was registered in the country. However, the diagnosis and treatment of HDV are still carried out within the protocols for hepatitis B.
ECAT members express concern that the lack of separate clinical guidelines and program documents for delta hepatitis diminishes the significance of this disease and limits opportunities for funding and planning patient assistance.
The letter also cites data from the Republican Center for the Control of Hemocontact Viral Hepatitis and HIV, indicating that as of September 1, 2025, 17% of patients with hepatitis B (3,120 individuals) have co-infection with delta hepatitis.
In light of the above, ECAT representatives propose that the Ministry of Health consider two main steps:
- to create a working group involving the patient community to develop and implement a national program for delta hepatitis with a separate budget,
- to develop and approve clinical guidelines for HDV as an independent nosology.
Photo on the main page is illustrative: gemotest.ru.
